Biostage Inc  

(Public, NASDAQ:BSTG)   Watch this stock  
Find more results for JOHN F. MCNAUGHTON
1.09
-0.01 (-0.91%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.08 - 1.12
52 week 0.53 - 3.47
Open 1.10
Vol / Avg. 40,801.00/132,924.00
Mkt cap 18.64M
P/E     -
Div/yield     -
EPS -0.97
Shares 14.11M
Beta     -
Inst. own 28%
Aug 11, 2016
Q2 2016 Biostage Inc Earnings Release - 9:30AM EDT - Add to calendar
Aug 11, 2016
Q2 2016 Biostage Inc Earnings Call - 9:00AM EDT - Add to calendar
May 12, 2016
Q1 2016 Biostage Inc Earnings Release
May 12, 2016
Q1 2016 Biostage Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -9918.65%
Operating margin - -9916.10%
EBITD margin - -9511.02%
Return on average assets -127.76% -144.85%
Return on average equity -136.96% -158.20%
Employees 18 -
CDP Score - -

Address

84 October Hill Rd Ste 11
HOLLISTON, MA 01746-1371
United States - Map
+1-774-2337300 (Phone)
+1-774-2337302 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Biostage, Inc., formerly Harvard Apparatus Regenerative Technology, Inc., is a biotechnology company. The Company is engaged in developing bioengineered organ implants based on its Cellframe technology. Its Cellframe technology consists of a biocompatible scaffold that is seeded with the recipient's own cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, trachea or bronchus that are caused due to cancer, infection, trauma or congenital abnormalities. Its Cellframe technology is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. Its Cellframe technology platform is used to create organ specific Cellspan implants. Its product candidates are in development and have not yet received regulatory approval for sale anywhere in the world.

Officers and directors

John F. Kennedy Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
James J. McGorry President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Thomas McNaughton Jr. Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Saverio La Francesca M.D. Executive Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
Harout DerSimonian Chief Scientific Officer
Bio & Compensation  - Reuters
David M. Green Director
Age: 50
Bio & Compensation  - Reuters
Blaine H Mckee Ph.D. Director
Bio & Compensation  - Reuters
John J. Canepa Independent Director
Age: 59
Bio & Compensation  - Reuters
Thomas H. Robinson Independent Director
Age: 56
Bio & Compensation  - Reuters